| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
An antipsychotic agent used in schizophrenia. [PubChem] |
| Indication |
For the management of the manifestations of psychotic disorders such as schizophrenia |
| Pharmacology |
Loxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Pharmacologically, Loxapine is a tranquilizer for which the exact mode of action has not been established, however, it is believed that by antagonising dopamine and serotonin receptors, there is a marked cortical inhibition which can manifest as tranquilization and suppression of aggression. |
| Toxicity |
LD50=65 mg/kg (Orally in mice) |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic |
| Absorption |
Systemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers |
| Half Life |
Oral-4 hours |
| Elimination |
Metabolites are excreted in the urine in the form of conjugates and in the feces unconjugated. |
| References |
| • |
Glazer WM: Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999;60 Suppl 10:42-6.
[Pubmed]
|
| • |
Cheung SW, Tang SW, Remington G: Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1991 Mar 8;564(1):213-21.
[Pubmed]
|
|
| External Links |
|